VELO Veloxis Pharmaceuticals A/S

Notice to Convene Extraordinary General Meeting

Notice to Convene Extraordinary General Meeting

Company Announcement no. 11/2020

To: NASDAQ Copenhagen A/S                                          

Copenhagen, Denmark, 24 January 2020



Notice to Convene Extraordinary General Meeting



Upon request from Asahi Kasei Pharma Denmark A/S, the board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 (the "Company"), hereby convenes an extraordinary general meeting in the Company to be held on

Monday 17 February 2020 at 12:00 p.m. CET

at the offices of Plesner Law Firm, Amerika Plads 37, 2100 Copenhagen, Denmark.

Shareholders who have accepted the voluntary recommended public offer shall disregard this convening notice as such shareholders have no rights to attend and vote at the Extraordinary General Meeting as their shares are sold.



Agenda

1                    Election of new members of the board of directors of Veloxis Pharmaceuticals A/S (current members are expected to resign)



Please see attached document for complete proposals. 



For more information, please contact:

Veloxis Pharmaceuticals A/S

Craig A. Collard                                     Ira Duarte

President & CEO                                  CFO

Phone:                       Phone:

Email:                        Email:





Attachment

EN
24/01/2020

Underlying

VELOVeloxis Pharmaceuticals A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Veloxis Pharmaceuticals A/S

 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 Febru...

Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Company Release no. 13/2020 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 17 February 2020 Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Today, Veloxis Pharmaceuticals A/S' Extraordinary General Meeting passed the following resolutions: The following persons were elected as members of the Board of Directors: Masaya EtohDaisuke MatsuoMatthew Ryan Dumont                    The elected board members replace all current membe...

February 17, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmace...

Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmaceuticals A/S' Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Selskabsmeddelelse nr. 12/2020 Til: NASDAQ Copenhagen A/S                                                  København, Danmark, 29. januar 2020   Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmaceuticals A/S' Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S   Som meddelt ved selskabsmeddelelse nr. 10/2020 har Veloxis Pharmaceuticals A/S ("Veloxis"), eft...

January 29, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Reques...

Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S Company Release no. 12/2020 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 29 January 2020 Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S As announced in company release no. 10/2020, Veloxis Pharmaceuticals A/S ("Veloxis") has, upon request from Asahi Kasei Pharma Denmark A/S, requested Nasdaq Copenhagen A/S ("Nasdaq Cop...

January 29, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Notice to Convene Extraordinary General Meeting

Notice to Convene Extraordinary General Meeting Company Announcement no. 11/2020 To: NASDAQ Copenhagen A/S                                           Copenhagen, Denmark, 24 January 2020 Notice to Convene Extraordinary General Meeting Upon request from Asahi Kasei Pharma Denmark A/S, the board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 (the "Company"), hereby convenes an extraordinary general meeting in the Company to be held on Monday 17 February 2020 at 12:00 p.m. CET at the offices o...

January 24, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceutical...

Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Selskabsmeddelelse nr. 10/2020 Til: NASDAQ Copenhagen A/S                                                  København, Danmark, fredag den 24. januar 2020 Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Med henvisning til selskabsmeddelelse nr. 9/2020, i hvilken Asahi Kasei Pharma Denmark A/S offentliggjorde sin beslutning om at udnytte sin ret til at gennemføre en tvangsindløsning af aktierne ejet af Vel...

January 24, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch